Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man

[1]  Paris Jean Aicardi,et al.  Diseases of the Nervous System: Clinical Neuroscience and Therapeutic Principles , 2004, European Child & Adolescent Psychiatry.

[2]  Yasushi Hiraoka,et al.  Mutations in Dynein Link Motor Neuron Degeneration to Defects in Retrograde Transport , 2003, Science.

[3]  J. Sanes,et al.  Inhibiting Axon Degeneration and Synapse Loss Attenuates Apoptosis and Disease Progression in a Mouse Model of Motoneuron Disease , 2003, Current Biology.

[4]  Shin J. Oh,et al.  Mutant dynactin in motor neuron disease , 2003, Nature Genetics.

[5]  Robert G. Miller,et al.  Drug therapy for amyotrophic lateral sclerosis: Where are we now? , 2003, IDrugs : the investigational drugs journal.

[6]  J. Rothstein,et al.  Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS , 2002, Annals of neurology.

[7]  M. Pinter,et al.  Reduced neuromuscular quantal content with normal synaptic release time course and depression in canine motor neuron disease. , 2002, Journal of neurophysiology.

[8]  S. Wiese,et al.  Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease , 2002, The Journal of cell biology.

[9]  G. Mckhann,et al.  Pathophysiology of nerve and root disorders , 2002 .

[10]  E. Salido,et al.  A missense mutation in Tbce causes progressive motor neuronopathy in mice , 2002, Nature Genetics.

[11]  V. Perry,et al.  Axon pathology in neurological disease: a neglected therapeutic target , 2002, Trends in Neurosciences.

[12]  J. Melki,et al.  Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. , 2002, Human molecular genetics.

[13]  D. Howland,et al.  Disruption of Dynein/Dynactin Inhibits Axonal Transport in Motor Neurons Causing Late-Onset Progressive Degeneration , 2002, Neuron.

[14]  M. Gurney,et al.  Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Caroni,et al.  Early and Selective Loss of Neuromuscular Synapse Subtypes with Low Sprouting Competence in Motoneuron Diseases , 2000, The Journal of Neuroscience.

[16]  M. Raff,et al.  Evidence That Wallerian Degeneration and Localized Axon Degeneration Induced by Local Neurotrophin Deprivation Do Not Involve Caspases , 2000, The Journal of Neuroscience.

[17]  D. Cleveland,et al.  Slowing of axonal transport is a very early event in the toxicity of ALS–linked SOD1 mutants to motor neurons , 1999 .

[18]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .

[19]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. , 1998, Glia.

[20]  J. Trojanowski,et al.  Neurofilaments and Orthograde Transport Are Reduced in Ventral Root Axons of Transgenic Mice that Express Human SOD1 with a G93A Mutation , 1997, The Journal of cell biology.

[21]  R. Vejsada,et al.  Clinical and molecular aspects of motoneurone diseases: animal models, neurotrophic factors and Bcl-2 oncoprotein. , 1997, Trends in pharmacological sciences.

[22]  F. Finiels,et al.  Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study. , 1996, Neuroreport.

[23]  R. Coggeshall,et al.  Methods for determining numbers of cells and synapses: A case for more uniform standards of review , 1996, The Journal of comparative neurology.

[24]  J. Glass,et al.  Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia , 1995, Annals of neurology.

[25]  M. Gurney,et al.  Age-Dependent Penetrance of Disease in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1995, Molecular and Cellular Neuroscience.

[26]  T. Deckwerth,et al.  Neurites can remain viable after destruction of the neuronal soma by programmed cell death (apoptosis). , 1994, Developmental biology.

[27]  J. Rothstein,et al.  Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[29]  M. Graeber,et al.  Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells , 1988, Journal of neuroscience research.

[30]  J. Griffin,et al.  Axonal transport in neurological disease , 1988, Annals of neurology.

[31]  M. Graeber,et al.  Reaction on Motoneurons and Their Microenvironment to Axotomy , 1986 .

[32]  E. K. Bjornskov,et al.  Quantitative axon terminal and end-plate morphology in amyotrophic lateral sclerosis. , 1984, Archives of neurology.

[33]  W. Bradley,et al.  Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis , 1983, Annals of neurology.

[34]  G. Sobue,et al.  Amyotrophic lateral sclerosis. Lack of central chromatolytic response of motor neurocytons corresponding to active axonal degeneration. , 1983, Archives of neurology.

[35]  Cavanagh Jb.  The significance of the "dying back" process in experimental and human neurological disease. , 1964 .